bioasia.in - publications

:: publications | BioAsia ::

Bioasia.in Spined HTML

:: publications | BioAsia :: Home Sitemap -- Quick Links -- Home The focus Organizers FABA Pharmexcil Industry Speak BioAsia 2012 BioAsia 2011 BioAsia 2010 BioAsia 2009 Proceedings 2012 Proceedings 2011 Proceedings 2010 Proceedings 2009 Awards-2012 Awards-2011 Awards-2010 Awards-2009 Photo Gallery 2012 Photo Gallery 2011 Photo Gallery 2010 Photo Gallery 2009 Video Gallery 2012 Video Gallery 2011 Presentation Publications Contact Us home well-nigh bioasia Focus Organizers industry speak archives bioAsia 2012 bioAsia 2011 bioAsia 2010 bioAsia 2009 Gallery Photo Video Presentation publications NewsTrack contact us publications Home Publications Biotech... ...under the Public Private Partnership('PPP') model A report on opportunities and challenges Biotechnology in India is one of the fastest growing sectors and is expected to protract playing a pivotal role in shaping India into a knowledge economy. Some of the key factors which offer India a competitive wholesomeness include the availability of research and minutiae (R&D) facilities, knowledge, skills and forfeit effectiveness. The Indian Bio-tech industry currently holds 2% of the global biotech market which is largely dominated by the US (with a share of 41%). Despite a global meltdown and reduced wanted flows into emerging countries, the Indian biotech industry has recorded a growth of 18% in rupee terms at Rs 121 billion. With long gestation periods and upper technical complexities, funding in Indian biotech minutiae companies has been highly diffused. While various incubation models have been tested in the US, Europe, Brazil and China, in India, such incubation clusters are well-matured in a few select cities with government agencies and institutes emerging as the innovation hubs. Up to 2009, the Biotech industry in India has had to rely largely on government support in the form of grants, parks, fiscal incentives etc with limited participation from Indian corporates. Even though PrivateProbity('PE') and VentureWanted('VC') funding has been flowing into India over the last 5 years, it has not been worldly-wise to lend the required thrust to biotech. Only a small fraction of the PE and VC investments are invested in biotech innovation owing to the complexity, uncertainty, long gestation period and risk involved in such setups. Role of PPP in Biotech India through its Public Funded R&D snout is encouraging researchers and wonk institutions to innovate and plans to incentivise their efforts. Government funding in terms of providing finance, inward into PPPs, their transferral in developing this sector is encouraging with their dual roles of the financier and the regulator. This report attempts to outline a model comprising government participation through public private partnerships for the minutiae of this sector, combining it with probity and knowledge participation from the private sector and using the results for social benefit. How these concepts may be implemented, is discussed in this report by addressing the pursuit key questions: Has government support wilt the dominant financing form for this sector? What are the current schemes and support mechanisms which are once in place? Can PPP play a pivotal role in the minutiae of this sector? What are the key opportunities under the PPP model? Understanding the value expectation of the public and the private partners What is in it for the government? Various funding schemes - tried and/or tested Case studies - successes and failures What are the key challenges on the road ahead? Are there any other innovative investments and return models? What is the way forward for PPP in Biotech? Hide Click here to get your self-ruling reprinting of this report Funding options... ..for Drug Discovery Companies A report on national and international models Research &Minutiae(R&D) activities, in particular, drug discovery requires well-matured efforts at various levels, multiple skills and expertise. The global drug discovery industry is facing considerable challenges due to increasing costs, decreasing productivity, funding pressures and sorriness of projects as they progress through the minutiae process. Companies and health organisations wideness the world are responding with wide-stretching re-organisation, restructuring and re-focusing in order to write the issues virtually R&D productivity, process inefficiency, project sorriness and the increasing financing of taking a potential new drug to the market and to secure profits. Global structural changes have created an thoroughfare for the Indian drug discovery companies who are trying to move up the value uniting from stuff generics to NCEs. The efforts of the Indian Government to finance R&D through its Public Funded R&D snout and the setting up of a Rs 20 billion venture wanted fund to finance research and minutiae work, is encouraging with the government vicarial as a financier as well as steering regulations. With large pharma companies having separated their discovery and research activities to enhance their focus and transferral towards the area, the drug discovery and research industry at large has been unable to secure significant investment independently. One of the primary reasons for the unwillingness of venture capitalists and investors to fund early stage minutiae is that drug discovery enterprises, which usually have long lead times of research activities, are moreover typically unable to propose viable exits. This, when coupled with the often poor availability of true venture wanted funding in India, limits the funding options for drug discovery. To make R&D partnerships work financially, and make the research count, the early stage drug discovery work must be properly funded and rewards should be shared equitably. Commercial investors are largely reluctant to withstand the full financing and the long term work associated with drug discovery. While the industry will sooner withstand the large financing associated in the latter clinical phases, the range of partnering options misogynist during the research phase are limited. This report attempts to outline some innovative funding models misogynist for drug discovery for variegated sized and variegated stage research agencies in India and attempts to outline the factors to be considered surpassing choosing an towardly model by answering the pursuit questions: Do all R&D companies share the same financing model? What are the hair-trigger success factors for choosing a particular investment and financing model? What have been the traditional financing models used in this sector? Are there any new and creative financing approaches misogynist to young discovery companies? Case Studies - successes and failures What are the variegated exit scenarios available? Hide Click here to get your self-ruling reprinting of this report The Asian Promise Key trends and alliances in biotechnology during 2010 The global biotechnology sector has witnessed various regional shifts - with the West emerging as the land of wanted and Asia shifting strategically from a mere outsourcing destination to a centre of innovation. In this paper, we struggle to bring out key drivers of this regional transformation in Asia and analyse this era of research-based alliances. Alliances that reward bio-innovation have been the name of the game in the global markets. The leaders of this bio-frenzy in the Asian region have been Japan, China and India, witnessing some of the largest deals of varying types: the traditional biotechpharma deals, biotech-biotech deals and ubiquitous M&As. The big pharma push towards generics in emerging markets; non-exclusive licensing arrangements in biotech; investment wanted provided by the West; faith in the discovery of biosimilars; and milestone-based alliances have been some of the innovative outcomes of this year's bio-deal monitor. Asia promises to wilt a biotechnology hub and this is made evident by the growing number of navigate verge collaborations in this sector since 2010. The region's thriving biotechnology sector has been driving innovation on its own over the last decade - Asia is now set to be a significant centre of developmental expertise. A fact now undisputed and respected by the world, evident in the flurry of collaborations in 2010. Click here to get your self-ruling reprinting of this report T&C Privacy Notice 0408rdc.com For optimal viewing of this website, recommended browsers are Internet Explorer 7 and whilom versions, Chrome, Firefox and Safari This website can be weightier viewed in 1152 x 864 screen resolution.